Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.30 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21858971 | 1.00 | HCRTR1 (0.32) | HCRTR1HCRTR2BDKRB2HTR3EHTR3B | |
| SCHEMBL23910533 | 0.89 | KDM4E (0.38) | HCRTR1HCRTR2HTR3EHTR3BCHRNA7 | |
| SCHEMBL23910536 | 0.89 | KDM4E (0.38) | HCRTR1HCRTR2HTR3EHTR3BCHRNA7 | |
| SCHEMBL23910521 | 0.85 | DRD2 (0.32) | — | |
| SCHEMBL23910522 | 0.85 | DRD2 (0.32) | — | |
| SCHEMBL13297989 | 0.82 | KDM4E (0.34) | HCRTR1HCRTR2ROCK2 | |
| SCHEMBL22443165 | 0.81 | FKBP1A (0.34) | HCRTR1HCRTR2TRPC6 | |
| SCHEMBL22443164 | 0.81 | FKBP1A (0.34) | HCRTR1HCRTR2TRPC6 | |
| SCHEMBL21840235 | 0.80 | HCRTR1 (0.38) | HCRTR1HCRTR2ROCK2 | |
| SCHEMBL20541621 | 0.80 | HCRTR1 (0.38) | HCRTR1HCRTR2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | BCR, MCL1, CD79B | HCRTR1 523/4885HCRTR2 339/4885BDKRB2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.